Illumina, Inc.
Illumina Reports Third Quarter 2024 Financial Results
Summary
Illumina, Inc. announced its financial results for the third quarter of fiscal year 2024, reporting Core Illumina revenue of $1.08 billion, down 2% from the prior year. The company's GAAP operating margin was 68.6%, and non-GAAP operating margin was 22.6%. The company also provided updated guidance, lowering its fiscal year 2024 Core Illumina revenue guidance and raising its non-GAAP operating margin and EPS guidance.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement